What WuXi TIDES does

WuXi TIDES is an integrated Contract Research, Development and Manufacturing Organization (CRDMO) platform - and an integral business unit of WuXi AppTec (Shanghai Stock Exchange: 603259.SS) - that provides end-to-end services for oligonucleotides, peptides, and related synthetic conjugates collectively termed 'TIDES' drugs. The platform serves global pharmaceutical and biotechnology customers from discovery synthesis through commercial API and drug product, covering custom oligonucleotide and peptide synthesis, conjugate development, monomer/ligand and unnatural amino acid manufacturing, process R&D, CMC, analytical testing, and regulatory dossier preparation for IND, CTA, MAA, and NDA submissions in the U.S., China, and EU. Programs across more than 20 clinical-stage GLP-1 candidates and a 2023 throughput of 50+ peptide projects and 15+ metric tons of peptide APIs illustrate the breadth of the installed customer base, which extends to more than 6,000 customers via the parent WuXi AppTec open-access platform.

The technology stack is organized around specialized, scale-intensive infrastructure rather than a single proprietary molecule. WuXi TIDES operates over 41,000 L of solid-phase peptide synthesis (SPPS) reactor volume across Changzhou and Taixing, roughly 30 oligonucleotide manufacturing lines of varying scale, a multi-channel micro-mixer sterile lipid nanoparticle (LNP) formulation platform for 10-50 L batches, an HPAPI plant with OEL capability down to 10 ng/m3, and a multicolumn countercurrent solvent gradient purification (MCSGP) continuous-flow system. A 169-acre Taixing API campus, a 33-acre Changzhou R&D Center (170+ labs; 3,000+ scientists at full operation), a 190-acre Delaware campus (operations 2026) and a 50-acre Singapore campus (operations 2027) - collectively backed by roughly $1.6 billion in committed capacity investment - position the platform to expand TIDES manufacturing capacity roughly threefold over 2023-2027.

Revenue is generated through project-based, multi-year CRDMO contracts priced by molecule type, development stage, scale, and service scope, and is captured indirectly through the publicly listed parent (WuXi AppTec does not break out WuXi TIDES as a separate segment). Distribution is direct enterprise sales augmented by industry events such as DCAT Week and the WuXi TIDES Forum, with technical expertise and integrated one-roof delivery acting as the principal sales differentiators. Operating geographies span China (Shanghai Waigaoqiao HQ; Changzhou, Taixing, Wuxi City, Wuhan, Chengdu, Tianjin), the United States (Middletown, Delaware), Switzerland (Couvet, acquired from Bristol Myers Squibb in August 2021), and Singapore (in build-out), with products commercially launched in 105 countries and the platform having cleared more than 50 inspections from FDA, EMA, NMPA, Japan PMDA, SwissMedic, and Brazil ANVISA.

Name

WuXi TIDES

Legal name

Shanghai SynTheAll Pharmaceutical Co., Ltd.

Website

https://tides.wuxiapptec.com

Company type

Private

Operating status

Operating

Short description

WuXi TIDES is an integrated CRDMO platform within WuXi AppTec, providing end-to-end contract research, development, and manufacturing services for oligonucleotides, peptides, and synthetic conjugates to global pharmaceutical and biotechnology sponsors across the full drug lifecycle.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Development and Manufacturing (CDMO/CRDMO)

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Chiral / Asymmetric Synthesis & Complex Chemistry Services (HLAGAHAE)

akta.pro secondary industries

Analytical Development & QC Testing (Release/Stability/Potency) (HLAGAGAF), Quality Engineering & Risk Management (ICH Q9/Q10, validation, change control) (HLAGAKAL), Release Testing & Batch Certification (QC) (HLAGADAC)

Keywords

• Oligonucleotide manufacturing services
• Peptide CDMO services
• TIDES drug development
• Contract research manufacturing
• Synthetic conjugate development

Headquarters

HQ city

Wake Forest

HQ country

United States

HQ region

North America

Offices10 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Contract Manufacturing Services: WuXi TIDES generates revenue through providing integrated contract research, development, and manufacturing services for oligonucleotides, peptides, and synthetic conjugates. Services span discovery synthesis, CMC development, API manufacturing, drug product manufacturing, analytical testing, and regulatory dossier preparation. Revenue is generated through project-based contracts with pharmaceutical and biotech companies.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

WuXi TIDES is an integrated Contract Research, Development and Manufacturing Organization (CRDMO) platform that provides end-to-end services for oligonucleotides, peptides, and related synthetic conjugates (TIDES drugs). Its offerings span discovery synthesis, process development, CMC development, API manufacturing, drug product manufacturing, analytical testing, and regulatory dossier preparation, delivered through 10+ R&D and manufacturing sites across Asia, North America, and Europe. The platform combines large-scale solid-phase peptide synthesis (over 41,000 L reactor volume), approximately 30 oligonucleotide manufacturing lines, sterile lipid nanoparticle formulation, and regulatory expertise spanning FDA, EMA, NMPA, SwissMedic, PMDA, and ANVISA inspections.

Product overview

WuXi TIDES is an integrated Contract Research and Development Manufacturing Organization (CRDMO) platform that provides end-to-end services for oligonucleotides, peptides, and related synthetic conjugates ('TIDES' drugs). The platform combines discovery synthesis, process development, API manufacturing, drug product manufacturing, analytical services, and regulatory dossier preparation under one roof. Key service offerings include custom oligonucleotide synthesis, peptide synthesis, conjugate development, unnatural amino acids, API CMC development, formulation development for oral and injectable dosage forms, and comprehensive analytical testing. The platform operates across multiple global facilities and supports clients from discovery through commercial stages. Notable technology platforms include solid-phase peptide synthesis (SPPS) with over 41,000 L total reactor volume, lipid nanoparticle (LNP) formulation for sterile injectables, and sustainable manufacturing processes with reduced environmental impact.

Differentiator

Problem solved

Functional benefit

Products and services

• Oligonucleotide Services End-to-end oligonucleotide development and manufacturing services including discovery synthesis, custom oligonucleotide synthesis, conjugate development, monomer and ligand manufacturing, API CMC development, drug product manufacturing, and analytical services, for pharmaceutical and biotech sponsors developing oligonucleotide therapeutics.
• Peptide Services Comprehensive peptide development and manufacturing services including discovery synthesis, custom peptide synthesis, conjugate development, unnatural amino acid development, API CMC development, drug product manufacturing, and analytical services, for pharmaceutical and biotech sponsors developing peptide therapeutics.
• Catalog Product (Amidite & Unnatural Amino Acid) Catalog products including amidite catalog and unnatural amino acid catalog for research and development purposes, available for purchase by researchers and developers.
• API Development and Manufacturing Process R&D and API manufacturing services for oligonucleotides, peptides, and complex synthetic conjugates from preclinical to commercial scale, provided to pharmaceutical and biotech sponsors.
• Drug Product Manufacturing Pre-formulation, formulation development, and manufacturing services for oral and injectable dosage forms including tablets, capsules, and sterile products, provided to pharmaceutical and biotech sponsors.
• Analytical Services Comprehensive analytical method development, validation, quality control, and stability studies supporting drug development from discovery through clinical to commercial stages, provided to pharmaceutical and biotech sponsors.
• Regulatory Dossier Preparation CMC documentation support for IND, CTA, MAA, and NDA applications in USA, China, and EU countries, provided through an experienced regulatory affairs team for pharmaceutical and biotech sponsors.

Quantifiable outcome

• IND filing completed in 10 months for GLP-1/GCG dual peptide program
• +5 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Six partnerships are on record, tiered core.

• Hoth TherapeuticscoreStrategic or Co-development Partner · 8 November 2021Contracts for process development and manufacturing of HT-KIT (morpholino oligonucleotide therapy) API and drug product. WuXi STA providing GMP manufacturing scale-up from feasibility batches to GMP material for parenteral formulation.
• InnoCare PharmacoreStrategic or Co-development Partner · 16 July 2021Strategic CDMO partnership where WuXi STA becomes preferred partner for InnoCare's pipeline projects of small molecule, oligonucleotide, peptide and complex chemical conjugate. WuXi STA supported orelabrutinib development and commercialization including API, amorphous solid dispersion, tablet manufacturing and packaging.
• Ascentage PharmacoreStrategic or Co-development Partner · 3 June 2021WuXi STA becomes preferred CDMO partner providing integrated CMC services for Ascentage Pharma's entire pipeline including process development and manufacturing of drug substances and products, regulatory support for IND filing, and commercial manufacturing.
• Bristol Myers SquibbcoreStrategic or Co-development Partner · 2 February 2021WuXi STA agreed to purchase Bristol Myers Squibb's manufacturing facility in Couvet, Switzerland. Acquisition completed in August 2021. Facility provides WuXi STA's first European presence with commercial-scale tablet & capsule manufacturing.
• AntengenecoreStrategic or Co-development Partner · 1 February 2021Collaboration to advance ADC candidates into clinical stage. WuXi STA provides GMP manufacturing of linkers and payloads, WuXi Biologics handles monoclonal antibody process development and GMP manufacture, Antengene focuses on antibody discovery and development.
• Neuraly (D&D Pharmatech)coreStrategic or Co-development Partner · 1 January 2020WuXi TIDES enabled Neuraly's GLP-1/GCG dual agonist program DD01 for IND submission in just 10 months. WuXi TIDES delivered non-GMP material for GLP studies in 4 months, GMP API, drug product formulation, validated methods, and full CMC package.

Scale indicators27 records

Recent moves13 records

Expansion highlights6 records

Broad incumbents

• Lonza: One of the world's largest CDMOs with significant peptide, oligonucleotide, and bioconjugate capabilities alongside broader small molecule and biologics manufacturing. Overlaps with WuXi TIDES on TIDES modalities but operates a much wider portfolio.
• EUROAPI: European CDMO spun out of Sanofi with API and oligonucleotide manufacturing capabilities. Comparable to WuXi TIDES as a multi-modality API supplier, though smaller in peptide and oligonucleotide scale.
• Pharmaron: China-based fully integrated CRO/CDMO with API manufacturing, process R&D, and biologics services across China, U.S., and U.K. sites. Comparable to WuXi TIDES in offering end-to-end development and manufacturing for global pharma customers.
• Piramal Pharma Solutions: India-headquartered CDMO with API and drug product services including peptide and high-potency capabilities across global sites. Competes with WuXi TIDES for complex API and contract manufacturing contracts from pharma and biotech.

Direct peers

• Bachem: Swiss-headquartered CDMO specializing in peptide and oligonucleotide API manufacturing with global sites in Switzerland and the U.S. Bachem is the most direct global competitor to WuXi TIDES in peptide SPPS capacity and TIDES-focused contract services.
• CordenPharma: Germany-based contract manufacturer with strong peptide, oligonucleotide, and complex API capabilities across multiple European and U.S. sites. Directly comparable to WuXi TIDES as a multi-modality CDMO serving pharma and biotech customers.
• STA Pharmaceutical (WuXi STA): Sister organization within WuXi AppTec providing small molecule CRDMO services; shares parent, governance, and integrated CMC platform with WuXi TIDES. Most directly comparable on business model, parent backing, and customer base.
• Asymchem: China-headquartered CDMO with growing peptide and oligonucleotide capabilities and a global customer base among innovative pharma companies. Direct comparable to WuXi TIDES on China-based CRDMO scale and integrated API/drug-product offerings.
• PolyPeptide Group: Switzerland-listed pure-play peptide and oligonucleotide CDMO serving pharma and biotech from preclinical through commercial. Highly comparable to WuXi TIDES' peptide API focus and customer base.

Emerging players

• Sai Life Sciences: India-based CRO/CDMO expanding into complex APIs, including peptides and oligonucleotides, serving global pharma innovators. Emerging competitor to WuXi TIDES for outsourced CMC and API manufacturing in the TIDES modality.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/wuxista

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about WuXi TIDES